Baku: Azerbaijan has demonstrated its capability to test for hantavirus using PCR methods, as confirmed by the World Health Organization (WHO), which highlights that the risk of the virus spreading remains low.

According to Azeri-Press News Agency, the WHO Representation in Azerbaijan responded to an inquiry from APA, stating that while the public risk is low, precautionary measures are in place to manage and prevent any potential outbreaks.

The WHO is collaborating with multiple countries under the International Health Regulations to ensure a swift response to hantavirus concerns. The organization is focusing its efforts on patient care, safety, and halting further spread of the virus. Hantavirus primarily spreads through contact with infected rodents, particularly their urine, droppings, or saliva. In rare cases, the virus can spread through person-to-person contact, primarily involving close, extended interactions.

The WHO has notified 12 countries with citizens who were recently on a ship associated with the virus, including nations such as Canada, Denmark, Germany, and the United States. In addition, WHO is assisting South Africa in following up with individuals from a related flight. The organization is also collaborating with Argentina to enhance understanding and response efforts given their experience with similar viruses.

In Azerbaijan, both human and animal health laboratories possess the capability to conduct PCR testing for hantavirus. WHO is also coordinating with European laboratories to ensure reliable testing for the Andes virus strain. If necessary, samples can be sent to specialized WHO reference laboratories for confirmation. Updated laboratory guidance will soon be released to support testing efforts across the region.

Globally, WHO assesses the risk of hantavirus as low, with moderate risk for those recently on the ship. The virus typically spreads from rodents to humans, with human-to-human transmission being very rare. Although there are thousands of cases reported worldwide each year, this number is relatively small compared to the global population.

Currently, there is no specific vaccine or antiviral treatment for hantavirus. Medical care focuses on monitoring and treating complications with the lungs, heart, or kidneys, with early medical attention improving outcomes. The WHO advises against relying on unproven treatments and encourages anyone who may have been exposed to seek guidance from health authorities.

Symptoms of hantavirus generally appear between one and eight weeks after exposure, with common symptoms including fever, fatigue, and breathing difficulties. The WHO urges the public to continue normal daily activities, follow public health advice, and obtain information from credible sources, while avoiding spreading unverified information or stigmatizing those affected. The organization emphasizes that the measures in place are designed to protect public health while maintaining transparency.